Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice

Toshio Nishikawa, Munenori Takaoka, Toshiaki Ohara, Yasuko Tomono, Huifang Hao, Xiaohong Bao, Takuya Fukazawa, Zhigang Wang, Kazufumi Sakurama, Yasuhiro Fujiwara, Takayuki Motoki, Yasuhiro Shirakawa, Tomoki Yamatsuji, Noriaki Tanaka, Toshiyoshi Fujiwara, Yoshio Naomoto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I α (HIF-1α), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 ± 722.0; temsirolimus, 599.2 ± 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024). These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome.

Original languageEnglish
Pages (from-to)230-236
Number of pages7
JournalCancer Biology and Therapy
Volume14
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Esophageal Neoplasms
Survival
Neoplasms
temsirolimus
Sirolimus
Therapeutics
Renal Cell Carcinoma
Nude Mice
Esophageal Squamous Cell Carcinoma
Up-Regulation
Animal Models
Phosphorylation
Cell Proliferation
Cell Line
Pharmaceutical Preparations

Keywords

  • Esophageal cancer
  • Molecular-targeted therapy
  • MTOR
  • Prolonged survival
  • Temsirolimus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. / Nishikawa, Toshio; Takaoka, Munenori; Ohara, Toshiaki; Tomono, Yasuko; Hao, Huifang; Bao, Xiaohong; Fukazawa, Takuya; Wang, Zhigang; Sakurama, Kazufumi; Fujiwara, Yasuhiro; Motoki, Takayuki; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Tanaka, Noriaki; Fujiwara, Toshiyoshi; Naomoto, Yoshio.

In: Cancer Biology and Therapy, Vol. 14, No. 3, 03.2013, p. 230-236.

Research output: Contribution to journalArticle

Nishikawa, T, Takaoka, M, Ohara, T, Tomono, Y, Hao, H, Bao, X, Fukazawa, T, Wang, Z, Sakurama, K, Fujiwara, Y, Motoki, T, Shirakawa, Y, Yamatsuji, T, Tanaka, N, Fujiwara, T & Naomoto, Y 2013, 'Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice', Cancer Biology and Therapy, vol. 14, no. 3, pp. 230-236. https://doi.org/10.4161/cbt.23294
Nishikawa, Toshio ; Takaoka, Munenori ; Ohara, Toshiaki ; Tomono, Yasuko ; Hao, Huifang ; Bao, Xiaohong ; Fukazawa, Takuya ; Wang, Zhigang ; Sakurama, Kazufumi ; Fujiwara, Yasuhiro ; Motoki, Takayuki ; Shirakawa, Yasuhiro ; Yamatsuji, Tomoki ; Tanaka, Noriaki ; Fujiwara, Toshiyoshi ; Naomoto, Yoshio. / Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. In: Cancer Biology and Therapy. 2013 ; Vol. 14, No. 3. pp. 230-236.
@article{e691030406db45a9ad3115c4d72bc3fb,
title = "Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice",
abstract = "Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3{\%}) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I α (HIF-1α), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 ± 722.0; temsirolimus, 599.2 ± 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024). These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome.",
keywords = "Esophageal cancer, Molecular-targeted therapy, MTOR, Prolonged survival, Temsirolimus",
author = "Toshio Nishikawa and Munenori Takaoka and Toshiaki Ohara and Yasuko Tomono and Huifang Hao and Xiaohong Bao and Takuya Fukazawa and Zhigang Wang and Kazufumi Sakurama and Yasuhiro Fujiwara and Takayuki Motoki and Yasuhiro Shirakawa and Tomoki Yamatsuji and Noriaki Tanaka and Toshiyoshi Fujiwara and Yoshio Naomoto",
year = "2013",
month = "3",
doi = "10.4161/cbt.23294",
language = "English",
volume = "14",
pages = "230--236",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice

AU - Nishikawa, Toshio

AU - Takaoka, Munenori

AU - Ohara, Toshiaki

AU - Tomono, Yasuko

AU - Hao, Huifang

AU - Bao, Xiaohong

AU - Fukazawa, Takuya

AU - Wang, Zhigang

AU - Sakurama, Kazufumi

AU - Fujiwara, Yasuhiro

AU - Motoki, Takayuki

AU - Shirakawa, Yasuhiro

AU - Yamatsuji, Tomoki

AU - Tanaka, Noriaki

AU - Fujiwara, Toshiyoshi

AU - Naomoto, Yoshio

PY - 2013/3

Y1 - 2013/3

N2 - Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I α (HIF-1α), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 ± 722.0; temsirolimus, 599.2 ± 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024). These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome.

AB - Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive cancers with poor prognosis regardless of a several reports that indicate a better therapeutic efficacy using some new chemotherapeutic agents. Recent drug development has contributed to an improved specificity to suppress mTOR activity by which many types of malignancies can be explosively progressed. Temsirolimus (CCI-779, TricelTM) is one of recently synthesized analogs of rapamycin and has provided better outcomes for patients with renal cell carcinoma. In this study, we experimentally evaluated an efficacy of targeting mTOR by temsirolimus for ESCC treatment, with an assessment of its survival advantage using an advanced ESCC animal model. First, we confirmed that the expression of phosphorylated mTOR was increased in 46 of 58 clinical ESCC tumor tissues (79.3%) and appeared to get strengthened with tumor progression. All of ESCC cell lines used in this study revealed an increase of mTOR phosphorylation, accompanied with the upregulation of hypoxia inducible factor-I α (HIF-1α), one of the critical effectors regulated by mTOR. Temsirolimus treatment apparently suppressed the activation of mTOR and its downstream effectors, resulting in the reduced ability of ESCC cell proliferation. Finally, the weekly administration of temsirolimus significantly diminished the size of subcutaneous tumors (vehicle, 3261.6 ± 722.0; temsirolimus, 599.2 ± 122.9; p = 0.007) in nude mice and effectively prolonged orthotopic esophageal cancer-bearing mice (median survival periods: control, 31 d; temsirolimus, 43 d; p = 0.0024). These data suggests that targeting mTOR by temsirolimus may become a therapeutic alternative for esophageal cancer, with a contribution to a better outcome.

KW - Esophageal cancer

KW - Molecular-targeted therapy

KW - MTOR

KW - Prolonged survival

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84874915753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874915753&partnerID=8YFLogxK

U2 - 10.4161/cbt.23294

DO - 10.4161/cbt.23294

M3 - Article

VL - 14

SP - 230

EP - 236

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 3

ER -